Literature DB >> 20660862

Progression of transthyretin amyloid neuropathy after liver transplantation.

Juris J Liepnieks1, Lucy Q Zhang, Merrill D Benson.   

Abstract

OBJECTIVE: To biochemically characterize peripheral nerve amyloid in subjects with transthyretin (TTR) amyloidosis and assess effect of orthotopic liver transplantation (OLT) on progression of neuropathy.
METHODS: Amyloid fibrils were isolated from peripheral nerve tissues of 6 patients with TTR amyloidosis who were heterozygous for an amyloid-associated TTR mutation. Ratio of variant to wild-type TTR in the fibrils was determined by amino acid sequencing of tryptic peptides containing either the variant amino acid residue or the corresponding normal amino acid.
RESULTS: Amyloid fibrils from 3 subjects who died without having received a liver transplant were composed of 60%-65% variant TTR and 35%-40% wild-type. Amyloid fibrils from a subject who died 5 years after liver transplantation contained 25% variant and 75% wild-type TTR.
CONCLUSION: Ratios of variant to wild-type TTR in amyloid patients heterozygous for an amyloid-associated TTR mutation are similar to published ratios for amyloid fibrils in cardiac tissue. Survival after liver transplantation for TTR amyloidosis may be associated with progression of neuropathy due to continued deposition of amyloid derived from wild-type TTR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660862      PMCID: PMC2918887          DOI: 10.1212/WNL.0b013e3181ea15d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients.

Authors:  M Yazaki; S Mitsuhashi; T Tokuda; F Kametani; Y-I Takei; J Koyama; A Kawamorita; H Kanno; S-I Ikeda
Journal:  Am J Transplant       Date:  2006-10-25       Impact factor: 8.086

2.  Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation.

Authors:  Juris J Liepnieks; Merrill D Benson
Journal:  Amyloid       Date:  2007-12       Impact factor: 7.141

3.  Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.

Authors:  Bert-Ove Olofsson; Christer Backman; Kjell Karp; Ole B Suhr
Journal:  Transplantation       Date:  2002-03-15       Impact factor: 4.939

4.  Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy.

Authors:  E A Pomfret; W D Lewis; R L Jenkins; P Bergethon; S W Dubrey; J Reisinger; R H Falk; M Skinner
Journal:  Transplantation       Date:  1998-04-15       Impact factor: 4.939

5.  Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis.

Authors:  A J Stangou; P N Hawkins; N D Heaton; M Rela; M Monaghan; P Nihoyannopoulos; J O'Grady; M B Pepys; R Williams
Journal:  Transplantation       Date:  1998-07-27       Impact factor: 4.939

6.  Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.

Authors:  Masahide Yazaki; Juris J Liepnieks; John C Kincaid; Merrill D Benson
Journal:  Muscle Nerve       Date:  2003-10       Impact factor: 3.217

7.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.

Authors:  Gustaf Herlenius; Henryk E Wilczek; Marie Larsson; Bo-Göran Ericzon
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

Review 8.  The molecular biology and clinical features of amyloid neuropathy.

Authors:  Merrill D Benson; John C Kincaid
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

9.  Familial amyloid polyneuropathy: a clinico-pathologic study.

Authors:  Gérard Said; Violaine Planté-Bordeneuve
Journal:  J Neurol Sci       Date:  2009-05-24       Impact factor: 3.181

10.  Tabulation of human transthyretin (TTR) variants, 2003.

Authors:  Lawreen Heller Connors; Amareth Lim; Tatiana Prokaeva; Violet A Roskens; Catherine E Costello
Journal:  Amyloid       Date:  2003-09       Impact factor: 7.141

View more
  39 in total

Review 1.  Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review.

Authors:  Adam Castaño; Sabahat Bokhari; Thomas H Brannagan; Julia Wynn; Mathew S Maurer
Journal:  Amyloid       Date:  2011-12-08       Impact factor: 7.141

Review 2.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

Review 3.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 4.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

5.  Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.

Authors:  Adam J Loavenbruck; Vinay Chaudhry; Steven R Zeldenrust; Robert J Spinner; Jason D Theis; Christopher J Klein
Journal:  Muscle Nerve       Date:  2012-11       Impact factor: 3.217

Review 6.  Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy.

Authors:  Philippe Kerschen; Violaine Planté-Bordeneuve
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

7.  Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease.

Authors:  Sandra Ihne; Caroline Morbach; Claudia Sommer; Andreas Geier; Stefan Knop; Stefan Störk
Journal:  Dtsch Arztebl Int       Date:  2020-03-06       Impact factor: 5.594

8.  Recent advances in the treatment of familial amyloid polyneuropathy.

Authors:  David Adams
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

9.  Diflunisal for ATTR cardiac amyloidosis.

Authors:  Adam Castaño; Stephen Helmke; Julissa Alvarez; Susan Delisle; Mathew S Maurer
Journal:  Congest Heart Fail       Date:  2012-07-02

10.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Authors:  John L Berk; Ole B Suhr; Laura Obici; Yoshiki Sekijima; Steven R Zeldenrust; Taro Yamashita; Michael A Heneghan; Peter D Gorevic; William J Litchy; Janice F Wiesman; Erik Nordh; Manuel Corato; Alessandro Lozza; Andrea Cortese; Jessica Robinson-Papp; Theodore Colton; Denis V Rybin; Alice B Bisbee; Yukio Ando; Shu-ichi Ikeda; David C Seldin; Giampaolo Merlini; Martha Skinner; Jeffery W Kelly; Peter J Dyck
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.